🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Relapsed / Refractory Solid Tumor

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). NCT06607692Phase 1, Phase 21 site📍 Boadilla del Monte Fundación de investigación HM · Tests: Olaparib; 177Lu-DOTATATE A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor NCT06615193Phase 18 sites📍 Zhengzhou📍 Suzhou📍 Suzhou Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Tests: HDM2005 A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors NCT06730659Phase 11 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: CHT101 Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites📍 Tucson📍 New Haven📍 Baltimore Calico Life Sciences LLC · Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deat… A Study of PHST001 in Advanced Solid Tumors NCT06840886Phase 120 sites📍 Beverly Hills📍 Los Angeles📍 Palo Alto Pheast Therapeutics · Tests: PHST001, Paclitaxel, Topotecan, Doxorubicin, FOLFIRI Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours NCT06430502NA1 site📍 Wuxi Wuxi People's Hospital · Tests: Tumor Treatment Vaccine; PD-1/L1 inhibitors A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) NCT06941272Phase 1, Phase 264 sites📍 Los Angeles📍 Aurora📍 New Haven Merck Sharp & Dohme LLC · Tests: Patritumab Deruxtecan ML-016 in Advanced Cancer With Lung and/or Liver Involvement NCT07723482Phase 1, Phase 23 sites📍 Miranda📍 Wollongong📍 Buderim BrYet US, Inc. · Tests: ML-016 HP007 Monotherapy for Relapsed or Refractory Advanced Solid Tumors NCT07800936Phase 11 site📍 Changchun Parr Biotechnology (Hebei) Co., Ltd. · Tests: HP007 KSH01-TCRT Solid Tumors NCT05539833EARLY Phase 11 site📍 Nanning TCRx Therapeutics Co.Ltd · Tests: KSH01 injection GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours NCT07297667Phase 14 sites📍 Calgary📍 Ottawa📍 Toronto Canadian Cancer Trials Group · Tests: Fludarabine, Cyclophosphamide, GCAR1 A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors NCT06063681Phase 13 sites📍 Randwick📍 Clayton📍 Frankston Stingray Therapeutics · Tests: SR-8541A, Immune checkpoint inhibitor (ICI) KSX01-TCRT Injection Project in Solid Tumors NCT05811975EARLY Phase 11 site📍 Nanning TCRx Therapeutics Co.Ltd · Tests: KSX01-TCRT injection Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors NCT06014502Phase 113 sites📍 Gilbert📍 Orange📍 Santa Monica ImmunoGenesis · Tests: IMGS-001 Evaluate the Safety and Clinical Activity of HH2853 NCT04390737Phase 1, Phase 225 sites📍 Phoenix📍 Jacksonville📍 Rochester Haihe Biopharma Co., Ltd. · Tests: HH2853 Tablets Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Becotatug Vedotin A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma NCT05341557Phase 14 sites📍 Chaoyang📍 Cangzhou📍 Tianjin Betta Pharmaceuticals Co., Ltd. · Tests: BPI-371153 B7-H3.CD28Z.CART in Solid Tumors NCT07358260Phase 11 site📍 Boston Robbie Majzner · Tests: B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma NCT07598955Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Cyclophosphamide, Fludarabine, EB-CAR30-NK, EB-CAR5-NK, EB-CARMSLN-NK Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors NCT06132503Phase 11 site📍 West Valley City Lantern Pharma Inc. · Tests: LP-284 Combination of CAR-DC Vaccine and ICIs in Malignant Tumors NCT05631886Phase 11 site📍 Beijing Chinese PLA General Hospital · Tests: TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide, anti-PD-1 antibody, Anti-CTLA4 Monoclonal Antibody A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors NCT06956690Phase 1, Phase 27 sites📍 La Jolla📍 Indianapolis📍 Farmington Hills Hummingbird Bioscience · Tests: ENV-501 A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) NCT07630974Phase 1, Phase 234 sites📍 Los Angeles📍 Aurora📍 St. Petersburg Merck Sharp & Dohme LLC · Tests: Ifinatamab Deruxtecan TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors NCT07713732Phase 13 sites📍 Camperdown📍 Malvern📍 Nedlands Treeline Biosciences, Inc. · Tests: TLN-499, Venetoclax A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment NCT04928677Phase 15 sites📍 Los Angeles📍 Atlanta📍 Boston Memorial Sloan Kettering Cancer Center · Tests: Codrituzumab SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors NCT06873659Phase 111 sites📍 Beijing📍 Beijing📍 Beijing Qurgen Inc. · Tests: SON-DP Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma NCT07502287Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-DTNB-NK, Fludarabine, Cyclophosphamide Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) NCT05521984Phase 11 site📍 St Louis Washington University School of Medicine · Tests: Dapagliflozin, Carmustine, Topotecan, Cyclophosphamide SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors NCT06936748Phase 21 site📍 Nanchang Second Affiliated Hospital of Nanchang University · Tests: Spatially Fractionated Radiation Therapy Followed by Sequential Hypofractionated or Conventional Fractionated Radiother… Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors NCT05533697Phase 1, Phase 239 sites📍 Los Angeles📍 San Francisco📍 Aurora ModernaTX, Inc. · Tests: mRNA-4359, Pembrolizumab, Ipilimumab, Nivolumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy